Knight Therapeutics Inc.

TSX:GUD.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$11.56 +0.75%

+$0.07 today

Market cap
$1.14B
Beta
0.07
P/E (TTM)
164.6
EPS (TTM)
$0.06
52W Low $5.66High $9.59

Volume 0.04M

Average 0.10M

GUD.TO Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Knight Therapeutics Inc.TSX: GUD.TO

Net Margin · Q1 FY2026 · quarter ended Mar 2026

Net margin widens to 8.9%

Net margin was 8.9% in Q1 FY2026, up 6.4 pp from a year earlier. On a trailing-twelve-month basis it was 1.1%, down 1.9 pp year over year. Over 3 fiscal years it widened by 9.0 pp.

Context

  • Net margin widened in 2 of the last 3 fiscal years.

What to watch

Whether net margin reaches the consensus estimate from 7 analysts of 2.4% for the fiscal year ending Dec 2026, up from -1.2% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
8.9%+2.2 pp QoQ
Last fiscal yearDec 2025
-1.2%-2.4 pp YoY
LTMMar 2026
1.1%-1.9 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+6.4 pp+12.7 pp+6.3 pp
1 year-2.4 pp+3.6 pp+6.0 pp
3 years+9.0 pp+7.7 pp-1.3 pp
5 years+8.7 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
-1.2%
Year-over-year change
-2.4pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How GUD.TO compares with its peers on the latest reported figures

  • GUD.TO's LTM Mar 2026 net margin of 1.1% is the 3rd highest of the 8 companies compared; the peer median is -12.1%.
  • Its year-over-year change of -1.9 pp is the 4th highest of 8, against a peer median of -4.4 pp.
  • Over three fiscal years its change of +9.0 pp compares with a peer median of +55.3 pp.
GUD.TO Competitors Peer median
Net Margin for GUD.TO and competitors
Company Period LTM level YoY 3-year change
CPH.TOCipher Pharmaceuticals Inc.LTM Mar 202660.8% +37.4 pp-74.7 pp
VHI.TOVitalhub Corp.LTM Mar 20266.1% +2.3 pp+2.6 pp
GUD.TOKnight Therapeutics Inc.LTM Mar 20261.1% -1.9 pp+9.0 pp
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026-9.2% -17.9 pp—
ACB.TOAurora Cannabis Inc.LTM Mar 2026-12.1% -12.6 pp+75.8 pp
KSI.TOKneat.com, Inc.LTM Mar 2026-12.7% -8.4 pp+34.8 pp
TSND.TOTerrAscend Corp.LTM Mar 2026-31.2% -4.4 pp+93.3 pp
WEED.TOCanopy Growth CorporationLTM Mar 2026-84.8% +137.6 pp+891.3 pp
Peer median (excluding GUD.TO) -12.1%-4.4 pp+55.3 pp

Competitors are the stored peer set for GUD.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue243.48M293.56M328.2M371.3M450.09M
Cost of Revenue128.07M155.5M175.55M196.9M299.35M
Gross Profit115.41M138.06M152.65M174.41M150.74M
Gross Margin47.4%47.0%46.5%47.0%33.5%
Research & Development12.69M14.76M17.55M23.3M28.98M
Selling, General & Admin74.38M88.62M83.69M99.35M123.96M
Operating Expenses128.24M155.12M155.54M167.01M152.94M
Depreciation & Amortization47.92M62.62M50.4M53.11M56.57M
EBITDA42.59M25.26M40.9M64.38M54.37M
EBITDA Margin17.5%8.6%12.5%17.3%12.1%
Operating Income(5.32M)(2.4M)(2.89M)7.4M(2.2M)
Operating Margin-2.2%-0.8%-0.9%2.0%-0.5%
Interest Income7.38M10.63M12.58M10.41M6.21M
Interest Expense3.62M6.6M12.49M9.22M10.42M
Other Income / Expenses19.52M(2.92M)(19.1M)(5.35M)(4.5M)
Income Before Tax6.69M(43.96M)(21.99M)2.05M(6.7M)
Pre-Tax Margin2.7%-15.0%-6.7%0.6%-1.5%
Income Tax Expense(8.99M)(14.07M)(5.15M)(2.28M)(1.33M)
Net Income15.68M(29.89M)(16.84M)4.33M(5.37M)
Net Margin6.4%-10.2%-5.1%1.2%-1.2%
EPS (Basic)0.13(0.26)(0.16)0.04(0.05)
EPS (Diluted)0.13(0.26)(0.16)0.04(0.05)
Weighted Avg Shares124.48M114.89M107.47M101.04M99.57M
Weighted Avg Shares (Diluted)124.52M114.89M107.47M101.44M99.57M

Knight Therapeutics Inc.

TSX:GUD.TO

Intrinsic Alpha fair value

Locked

Current Price

$11.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.